Inquiry Basket
CAS No.:
Cat No.: BADC-01476
4.5 
FCHFHS-ST7612AA1 is part of Antibody Drug Conjugate ADCs with HDAC inhibitor payload and linker for antitumor activity.
Structure of
* For research and manufacturing use only. We do not sell to patients.
| Size | Price | Stock | Quantity |
|---|---|---|---|
| -- | $-- | In stock |
Looking for different specifications? Click to request a custom quote!
Capabilities & Facilities
Popular Publications Citing BOC Sciences Products
FCHFHS-ST7612AA1 is an innovative compound that forms part of the emerging class of Antibody Drug Conjugates (ADCs), specifically utilizing HDAC inhibitor payloads and linkers. These complex biopharmaceuticals are designed to target specific cancer cells while minimizing damage to normal tissues, thereby offering potential advancements in oncology treatments. The incorporation of HDAC inhibitors as the payload ensures that the compound can effectively mediate antitumor activity by interrupting critical processes within the cancer cells that are essential for their proliferation and survival.
The significance of FCHFHS-ST7612AA1 in drug discovery lies in its unique dual-action mechanism, combining the targeted delivery capability of antibodies with the potent epigenetic modifying effects of HDAC inhibitors. Histone deacetylase (HDAC) inhibitors are known for their role in modulating gene expression and inducing cell cycle arrest, apoptosis, and differentiation. By conjugating such inhibitors to antibodies, FCHFHS-ST7612AA1 can specifically deliver these therapeutic effects to malignant cells, reducing off-target effects and potentially increasing the therapeutic window of HDAC inhibitors.
In the realm of oncology drug discovery, the development of FCHFHS-ST7612AA1 represents a strategic enhancement of ADC technology. The conjugation technology allows for precise linkage of the HDAC inhibitor to the antibody, ensuring stability and controlled release. This specificity not only drives the compound directly to cancerous tissues but also enhances the efficacy of the therapeutic payload. As traditional chemotherapy agents often lack specificity, leading to significant side effects, the approach utilized by FCHFHS-ST7612AA1 aims to mitigate these issues by improving selective toxicity towards tumor cells.
Furthermore, the research and development of FCHFHS-ST7612AA1 demonstrate the potential for ADCs to expand beyond traditional cytotoxic payloads. By employing HDAC inhibitors, which act through epigenetic rather than DNA-damaging mechanisms, there is a novel opportunity to address cancers that are resistant to more conventional forms of chemotherapy. This not only broadens the applicability of ADCs but also provides a promising avenue for tackling particularly aggressive or refractory cancers, which remain significant challenges in the field of cancer therapy.
FCHFHS-ST7612AA1
Required fields are marked with *
FCHFHS-ST7612AA1
Required fields are marked with *
Contact our experts today for pricing and comprehensive details on our ADC offerings.
From cytotoxin synthesis to linker design, discover our specialized services that complement your ADC projects.
Learn more about payload design, linker strategies, and integrated CDMO support through our curated ADC content.
Find exactly what your project needs from our expanded range of ADCs, offering flexible options to fit your timelines and goals.
